NeraCare develops and markets molecular diagnostic tests (genetic tests) for patients with black skin cancer (melanoma). The tests provide disease-specific information for each individual patient and are used to make individualized treatment decisions, i.e. whether further therapy is absolutely necessary after surgical removal of the melanoma or whether the survival prognosis of a patient, although already in advanced stage III with lymph node involvement, is nevertheless so favorable that drug therapy and the associated severe side effects can be dispensed with for the time being. Such an approach is called precision medicine and helps each patient to receive treatment tailored to his or her individual risk.
“Genetic analysis has opened up a new dimension in the treatment of skin cancer. The inclusion of genetic information means that patients can be treated more precisely. This means that in the future, treatment decisions will be made based on individual risk. Currently, this is already being implemented in the NivoMela study, and the next step will be to establish our tests in standard care.” Matthias Ackermann, Co-Founder and CEO
Neracare on the cooperation with MIG
“Matthias Kromayer brings his vast experience in VC financing and strategic alignment of start-ups in oncology. Thus, he also initiated the first acquisition of NeraCare during our discussions in order to cover a broader spectrum of melanoma patients and pharmaceutical companies with our product portfolio.” Matthias Ackermann, Co-Founder and CEO